Back to all assets

Smith & Nephew SN

equity

Price History

£1.3£7.42£13.53£19.65
1988-06 · DCA start£1.55

Time underwater

How far below its previous all-time high the price sat, each month. 0% means a new high.

-53.1%-35.4%-17.7%0.0%
1988-062026-08 · -44.2%

Worst drawdown: −53%, peaking Jul 2019 and bottoming Sep 2023 — still unrecovered after 78 months.

DCA Backtest

Invested
£42,100
Value today
£122,066
Return
+189.9%
Months invested
421

Scenarios

Inflation — the same contributions merely keeping pace with CPI would be £73,265 today, so the real (inflation-adjusted) return is +66.6%.

Lump sum instead — £42,100 all at once in Jun 1988: £298,573 (+609.2%) — lump sum came out ahead.

Worst timing — same monthly amount started at the all-time high (Jul 2019): £7,045 on £7,900 invested (-10.8%).

⚠ Price returns only — dividends are not included. This understates the true return of dividend-paying shares, and any comparison against crypto (which pays no dividends) is biased against equities by roughly the dividend yield, compounded.

If this saved you a spreadsheet — buy me a coffee.

Every start month at once

Each cell is the return-to-date of £/$/€100-a-month DCA started that month. Click a cell to load it in the backtest above. The ringed cell is the all-time-high start — the worst timing scenario.

JFMAMJJASOND
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Legend:−50%−20%0%+50%+200%+1000%worst timing (ATH)Selected 1988-06: +189.9%

About Smith & Nephew

Smith & Nephew plc, also known as Smith+Nephew, is a British multinational medical equipment manufacturing company headquartered in Watford, England. It is an international producer of advanced wound management products, arthroscopy products, trauma and clinical therapy products, and orthopaedic reconstruction products. Its products are sold in over 100 countries. It is listed on the London Stock Exchange and is a constituent of the FTSE 100 Index. (Wikipedia)

It's a listed company categorised under health care.

It rates Medium-High Risk at 2.3/5, meaning real but ordinary risk — the kind most mainstream assets carry, with some factors scoring poorly.

What pushes the score up: sector / regulatory (3.0/5) and leverage / financial (2.5/5).

Not yet researched: governance. These are excluded from the score rather than guessed, so the real risk may be higher than what’s shown.

Ratings summarise sourced facts against fixed rules — not investment advice, and no substitute for your own diligence.

Risk Profile

Medium-High Risk(2.3/5)90% rated

How these ratings work

Market / Volatility2.3/5 · weight 20%
  • Annualised volatility (3yr)3/527.1
  • Max drawdown from ATH3/553.1
  • Beta vs S&P 5001/50.14
Liquidity2.0/5 · weight 15%
  • Avg daily $ volume2/528.1m
  • Float % of shares outstandingnot yet researched
Leverage / Financial2.5/5 · weight 20%
  • Debt / equity2/50.63
  • Interest coverage (EBIT / interest)3/55.4
Earnings Quality2.0/5 · weight 15%
  • 3yr EPS volatility2/519.6
Concentration2.0/5 · weight 10%
  • Largest customer, % of revenuenot yet researched
  • Geographic revenue concentration2/5majority stable region
Governanceunrated · weight 10%
  • Board independence %not yet researched
  • Share structurenot yet researched
  • Litigation / audit historynot yet researched
Sector / Regulatory3.0/5 · weight 10%
  • Sector regulatory exposure3/5elevated

Linked Assets

Same sector, or return-correlated — worth knowing what else might move if this one does.